KalshiVerfügbarkeit prüfenKYC erforderlich2% GebührVerifizierte AuflösungsdatenGrob kalibriertAktuelle implizite WahrscheinlichkeitBefore Jul 1, 2027 50%-1.0%Führend unter 5 Optionen
Marktqualitat
52 / 100
Mittlere Qualität24h-Volumen
279,6 €
Liquidität
11.567,1 €
Mittlere LiquiditätGeld / Brief
46.0% / 50.0%
Spread
8.7%
Breiter SpreadMarktdaten
Aktualisiert vor 28 Minuten
14. Mai 26, 2:001. Juli 27, 3:59
Trends
Nur virtuelles Guthaben – kein echtes GeldKeine Finanzberatung
Gewähltes Ergebnis
Before Jul 1, 202750%
Volumentrend
$3182. Juli25T Daten26. Juli
Verwandte Märkte
New pandemic in 2026?
6231,9 €Ja: 7%
POLYMARKET
POLYMARKET
Hantavirus pandemic in 2026?
3245 €Ja: 3%POLYMARKET
POLYMARKET
Measles cases in 2026?
2546,6 €Above 4000: 39%KALSHI
KALSHI
Ebola pandemic in 2026?
1660,2 €Ja: 4%POLYMARKET
POLYMARKET
When will the FDA reclassify BPC-157 to Category 1?
1327,4 €Before September: 24%KALSHI
KALSHI
When "Will Masking Return"? (widespread mask mandates in the USA)
996,3 €September 2023: 1%MANIFOLD MARKETS
MANIFOLD MARKETSIn diesen Themen aktiv
Regeln
If the FDA approves retatrutide (LY3437943) for marketing before Jan 1, 2027, then the market resolves to Yes.
- An approval is defined as:
- For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application
- The following constitute approvals that trigger the Payout Criterion:
- Standard approval (traditional approval based on clinical benefit) Accelerated approval (based on surrogate endpoints) Approval with Risk Evaluation and Mitigation Strategy (REMS) Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs
- The following do NOT constitute approvals: